Skip to content

Crinetics Pharmaceuticals CRNX License — Milestone revenue

Similar metrics at other companies

Cytokinetics logo
CYTKLicense And Milestone Revenues — Revenue
$11.93M
Exelixis logo
EXELLicense revenues — Revenue from contract with customer, commercial sales milestone
$5.3M+393%
Axsome Therapeutics logo
AXSMMilestone Revenue — Revenue
$500K
Axsome Therapeutics logo
AXSMRoyalty And Milestone Revenue — Revenue
$1.8M+63.2%
Dianthus Therapeutics logo
DNTHMilestone — Revenue Recognition Milestone Method Pending
$15M0.0%
Incyte logo
INCYMilestone and contract revenues — Total revenues
$17M

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept crnx:MilestoneRevenue.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's license — milestone revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's license — milestone revenue?
Crinetics Pharmaceuticals (CRNX) reported license — milestone revenue of $1.5M in Q2 2026.
What does license — milestone revenue mean?
Revenue recognized upon the successful achievement of specific, contractually defined events such as regulatory approvals or clinical trial results. This metric tracks the realization of variable consideration within licensing agreements. It is a vital indicator of the company's ability to successfully advance its pipeline and convert research progress into financial results.